Conference Coverage

Piperacillin/Tazobactam Active Against Infections

Published in Cancer Weekly, July 31st, 1995

Potentially fatal infections in neutropenic cancer patients can be managed more effectively with the antibiotic piperacillin/tazobactam combined with amikacin than with the current standard therapy alone, according to a report from Belgium.

Newly reported studies also concluded that piperacillin/tazobactam is as effective as commonly used combination regimens or imipenem for the treatment of intra-abdominal infections and that the antibiotic is more effective than currently used regimens when combined with tobramycin, for hospital-acquired lower respiratory tract infections.

These studies were reported at the 19th International Congress of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry